Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site.
about
Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's diseaseHepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5AInhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceSelection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C VirusHepatitis C Virus (HCV) NS5B Nonnucleoside Inhibitors Specifically Block Single-Stranded Viral RNA Synthesis Catalyzed by HCV Replication Complexes In VitroCharacterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In VitroPyrophosphorolytic Excision of Nonobligate Chain Terminators by Hepatitis C Virus NS5B PolymeraseBinding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase InhibitorsStabilization of Poliovirus Polymerase by NTP Binding and Fingers–Thumb InteractionsStructure-function relationships among RNA-dependent RNA polymerasesA Locking Mechanism Regulates RNA Synthesis and Host Protein Interaction by the Hepatitis C Virus PolymeraseDevelopment of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors1,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside InhibitorsLoss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27–restricted human immune responseSlow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C VirusMutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C VirusStructure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic propertiesDiscovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and DockingAnalysis of the Resistance of Hepatitis C Virus NS5B Polymerase Inhibitors via Docking and Molecular Dynamics Simulation.Initiation of RNA synthesis by the hepatitis C virus RNA-dependent RNA polymerase is affected by the structure of the RNA template.Dynamics of hepatitis C virus (HCV) RNA-dependent RNA polymerase NS5B in complex with RNAStructure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase.UGGT1 enhances enterovirus 71 pathogenicity by promoting viral RNA synthesis and viral replicationCharacterization of thiobarbituric acid derivatives as inhibitors of hepatitis C virus NS5B polymerase.Dynamics on multiple timescales in the RNA-directed RNA polymerase from the cystovirus phi6Phosphorylation of hepatitis C virus RNA polymerases ser29 and ser42 by protein kinase C-related kinase 2 regulates viral RNA replication.Affinity labeling of hepatitis C virus replicase with a nucleotide analogue: identification of binding site.Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication.Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.Occurrence of genetic modifications in core, 5'UTR and NS5b of HCV associated with viral response to treatment.Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors.Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.Allosteric inhibitors have distinct effects, but also common modes of action, in the HCV polymerase.Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition.Challenges and successes in developing new therapies for hepatitis C.Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71.Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase.Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.
P2860
Q22248091-8A9EACA1-428C-461B-8118-EA57166831B7Q24303838-410F7779-329C-48A1-A9CD-758DC5CA1FD5Q26783056-9C58A13B-2548-4B0B-906C-9A226CA05332Q27473236-6F11E598-1CFD-4B26-932D-1F2921D27573Q27478063-BD200436-4D5C-4DB6-B6E8-E89B180E7CF0Q27480361-A7E2E123-B901-44AD-9FFF-887248F78C03Q27480921-5797EF4B-8D56-45D2-8FAF-5D4A7D090F8FQ27480926-B85F16A4-A3C8-4667-BFCD-EB0AB576C7DEQ27480973-CDF32C3D-310A-49F6-BFD4-C67E5D55F721Q27486391-AB7D8AB5-3257-4ABF-81AA-656C03AF5344Q27486419-B1D7B149-F1FC-432A-9184-F8E648B555E5Q27487022-C9A97408-7C27-4EB8-9D0B-A2CB332E7D15Q27487390-6F8FF6ED-B7DA-48C0-9F24-969C77DD2161Q27487784-8A29CDEC-62F2-4958-899C-1095A6927C7BQ27488887-73B55EC5-8A83-4AA4-BA21-ECD5B378F471Q27489369-4DE3A9C3-6723-40F8-BBF5-4C9F5D598C75Q27490956-265562D3-C7F2-49B6-A3F9-BDF75528E514Q27678311-8675DBF3-852D-468A-BE0E-E8DC48C46418Q28553112-17434BF0-FC25-465F-A2E4-CD2DC3E357BFQ30316803-1CD6E413-4FBC-451A-8605-8383A6A03082Q30317019-50A7F79B-3B3E-4A61-B531-F7F955F64336Q33619589-1060761B-2CE2-44F7-A005-E269F7B1CBE1Q33631936-F33BB7FB-0AB3-4943-BF9D-6FAE20F0C9C0Q33699539-544940D9-835E-4100-9D00-536C8F0A40CBQ33793620-3EB45375-ADE6-4D31-A35A-33452D32A0CEQ34080040-4EA55EED-F169-4AD5-8FC1-A6362C45FF01Q34261874-9EC6D2A0-AEF4-44B2-A050-5DBDFB65FB5DQ34523107-37FB0614-68DC-4A61-98D9-8DCAA602CE78Q34580349-947799ED-4941-4B3D-B0DC-0AF5FCC5D998Q34587192-45E75E1F-3FCF-4AD5-B324-F008DC0F07B9Q34597529-8D9E66A8-CE9C-4B8D-92BF-288407BE178EQ34896257-8523D7EC-78EE-4483-820F-5C13449F1A8AQ35248674-4FBFC09C-2273-4CB0-BE49-BD5670BED61BQ35260330-7EF2D02E-003B-468C-84E3-20BF0BA09715Q35333600-70FC89E0-67D2-465B-9D26-45DA3CE5FC70Q35526559-929510DF-743A-4548-A5FB-10801F47FCBFQ36233823-FC099A71-1706-499E-8E43-3FDA678F0B22Q37247709-A9CD9287-EBC0-4C5D-AB27-410FD79D3863Q37618717-A096389B-7A88-43F9-AA3C-66BC13789841Q37855859-924C189D-4CB0-437E-B634-B1F7075A3CAE
P2860
Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Interdomain communication in h ...... nd to a novel allosteric site.
@en
Interdomain communication in h ...... nd to a novel allosteric site.
@nl
type
label
Interdomain communication in h ...... nd to a novel allosteric site.
@en
Interdomain communication in h ...... nd to a novel allosteric site.
@nl
prefLabel
Interdomain communication in h ...... nd to a novel allosteric site.
@en
Interdomain communication in h ...... nd to a novel allosteric site.
@nl
P2093
P2860
P356
P1476
Interdomain communication in h ...... nd to a novel allosteric site.
@en
P2093
Andrea Carfí
Cinzia Volpari
Frank Narjes
Giovanni Migliaccio
Licia Tomei
Michael Rowley
Sergio Altamura
Stefania Di Marco
Steven Harper
P2860
P304
29765-29770
P356
10.1074/JBC.M505423200
P407
P577
2005-06-13T00:00:00Z